drugset / Trial / NCT00224523

Long Term Safety Of GW685698X Via Nasal Biopsy

NCT00224523

Phase 3 Completed 125 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

Long term safety (52 weeks) of GW685698X on the nasal mucosa via nasal biopsy with an active control group (Nasonex®) and a healthy volunteers control group in subjects 18 years old with perennial allergic rhinitis . Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. Perennial allergic rhinitis is triggered by house dust mites, animal dander, etc., possibly causing symptoms year-round including nasal congestion, rhinorrhea and/or nasal itching.

Timeline

Start
2005-09
Primary completion
2007-02
Completion
2007-02

Publications

  • Background Fokkens W, Hellings P, Blom H, Jansen A, van Drunen K, Clements D, Wu W, Caldwell M, Philpot E. A comparison of the effects of fluticasone furoate and mometasone furoate nasal sprays on the nasal mucosa. Ann Allergy Asthma Immunol 2008; 100(1) (Supplement 1):A12 (abstract)

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified 100 ug Intranasal
Subject Mometasone furoate Other / unclassified 200 ug Intranasal